Global trends in pharmacovigilance-related events: a 30-year analysis from the 2019 global burden of disease study
International Journal of Clinical Pharmacy · 2024
DOI: 10.1007/s11096-024-01738-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Clinical Pharmacy, 2024. Verfasst von Shuzhi Lin und 6 weiteren Autor:innen. Beteiligte Einrichtung: The Department of Pharmacy Administration, School of Pharmacy, Xi'an Jiaotong University, Xi'an, Shaanxi, China. Hauptthemen laut MEDLINE: Pharmacovigilance, Global Burden of Disease, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Project of the National Social Science Foundation of China, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
BACKGROUND: Establishing effective pharmacovigilance systems globally is challenging due to the need for comprehensive epidemiological data on pharmacovigilance-related events, particularly in countries at different stages of development. AIM: This study aimed to determine magnitude and drivers of change in the global and regional burden of pharmacovigilance-related events from 1990 to 2019, analyzing variations between age groups and sex, providing data support for policymakers to adjust their pharmacovigilance policies. METHOD: Pharmacovigilance-related events were defined as Adverse Effects of Medical Treatment (AEMT) and Drug Use Disorders (DUD) in the Global Burden of Diseases, Injuries, and Risk Factors Study 2019. Time trend analysis utilized joinpoint regression, age-period-cohort model, and decomposition method. Disease burden was measured in incidence, deaths, and disability-adjusted life years (DALYs). RESULTS: The global burden of pharmacovigilance-related events remained high, driven predominantly by population growth. Children and older adults were identified as particularly susceptible groups. Across various regions and periods of the socio-demographic index (SDI), the risk of death from AEMT showed a decreasing trend. In contrast, the incidence of AEMT and both the incidence and death rates from DUD showed a stable or worsening trend. Significant regional disparities in the burden of these diseases were noted between different SDI levels. CONCLUSION: The study underscores the critical need for robust pharmacovigilance systems worldwide. The observed trends in the burden of pharmacovigilance-related events offer a clear direction for countries to refine and strengthen their pharmacovigilance policies and practices.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The Department of Pharmacy Administration, School of Pharmacy, Xi'an Jiaotong University, Xi'an, Shaanxi, China.
- The Center for Drug Safety and Policy Research, Xi'an Jiaotong University, Xi'an, Shaanxi, China.
- The Department of Pharmacy Administration, School of Pharmacy, Xi'an Jiaotong University, Xi'an, Shaanxi, China. fengbianling@163.com.
- The Center for Drug Safety and Policy Research, Xi'an Jiaotong University, Xi'an, Shaanxi, China. fengbianling@163.com.
Förderung
- Project of the National Social Science Foundation of China
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Lin, S., Lei, S., Liu, W., Zhu, X., Yin, L., Liu, Q., & Feng, B. (2024). Global trends in pharmacovigilance-related events: a 30-year analysis from the 2019 global burden of disease study. International Journal of Clinical Pharmacy. https://doi.org/10.1007/s11096-024-01738-6
Vancouver
Lin S, Lei S, Liu W, Zhu X, Yin L, Liu Q, et al. Global trends in pharmacovigilance-related events: a 30-year analysis from the 2019 global burden of disease study. International Journal of Clinical Pharmacy. 2024. doi:10.1007/s11096-024-01738-6
BibTeX
@article{Lin2024,
author = {Lin, Shuzhi and Lei, Shuang and Liu, Wei and Zhu, Xiaoying and Yin, Lin and Liu, Qian and Feng, Bianling},
title = {Global trends in pharmacovigilance-related events: a 30-year analysis from the 2019 global burden of disease study},
journal = {International Journal of Clinical Pharmacy},
year = {2024},
doi = {10.1007/s11096-024-01738-6}
}
EUVIMED